Table 1 Clinical characteristics and medications
| Â | Control Subjects | HCM Subjects |
|---|---|---|
(n = 15) | (n = 15) | |
Age (years) | 48 ± 6 | 54 ± 12 |
Sex (Male/Female) | 7/8 | 11/4 |
BMI (kg/m2) | 29.3 ± 7.7 | 30.1 ± 5.2 |
Family history of HCM, n (%) | 0 (0%) | 5 (33%) |
Diabetes mellitus, n (%) | 1 (6%) | 0 (0%) |
Hypertension, n (%) | 3 (20%) | 5 (33%) |
Hyperlipidemia, n (%) | 3 (20%) | 8 (53%) |
Smoking history, n (%) | 4 (26%) | 1 (6%) |
Ventricular tachycardia, n (%) | 0 (0%) | 2 (13%) |
Angina, n (%) | 0 (0%) | 6 (40%)* |
ICD (%) | 0 (0%) | 2 (13%) |
HCM 5-year SCD risk (%) |  | 2.9 ± 1.2 |
NT-proBNP, median (pg/mL) [IQR] |  | 285 [91–910] |
Gene mutation positive, n (%) | Â | 6 (47%) |
Medications, n (%) | ||
 ACE-I/ARB | 4 (26%) | 2 (13%) |
 Beta blocker | 4 (26%) | 9 (60%) |
 Non-DHP calcium channel blocker | 1 (6%) | 4 (26%) |
 Disopyramide | 0 (0%) | 5 (33%)* |
 Amiodarone | 0 (0%) | 1 (6.7%) |
 Anti-platelet | 5 (33%) | 4 (26%) |
 Warfarin | 0 (0%) | 1 (6.7%) |